Navigation Links
BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
Date:9/4/2012

LYNBROOK, N.Y., Sept. 4, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the following two upcoming investor conferences in September:

  • Rodman & Renshaw 14th Annual Healthcare Conference
    Monday, September 10, 2012 at 11:40 am EDT
    New York, NY
  • ThinkEquity 9th Annual Growth Conference
    Thursday, September 13, 2012 at 9:30 am EDT
    New York, NY

The live webcasts of these presentations may be accessed under "Calendar of Events" in the Investor Relations section of the BioSpecifics' website at www.biospecifics.com. A replay of the webcasts will also be available on the Company's website following the presentations.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase (XIAFLEX®) for twelve clinical indications. Currently, XIAFLEX is marketed in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials.  Auxilium has entered into three strategic partnerships for development and commercialization outside the U.S. of injectable collagenase for Dupuytren's contracture and Peyronie's disease. Pfizer Inc. has rights in Europe and Eurasia and injectable collagenase is currently marketed as XIAPEX® for Dupuytren's contracture in select European countries. Asahi Kasei Pharma Corporation has rights in Japan and Actelion Pharmaceuticals Canada Inc. has rights in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
4. Medisafe 1 Technologies in Advanced Negotiations for $7MM Perpetual License Sale
5. Global E-Clinical Trial Technologies Industry
6. Antifungal Drugs: Technologies and Global Markets
7. Cleveland Clinics 2012 Medical Innovation Summit Highlights Orthopaedic Technologies
8. Breast Cancer Diagnostic and Drug Technologies: Global Markets
9. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
10. Montmed to Participate in 2013 Advanced Technologies and Treatments for Diabetes Conference
11. U.S. Navy Awards Multi-Million Dollar Contract to Innovation for Pharmacy Automation Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/7/2020)... ... April 07, 2020 , ... ... advising Physician Housecalls (PHC) on its investment by Council Capital (Council). PHC is ... rapidly expanding its current footprint in surrounding states. PHC will use this investment ...
(Date:4/7/2020)... ... 07, 2020 , ... The month of March saw a ... has led to an increased focus on customer safety and health, creating new ... How businesses and customers physically interact with each other has rarely been more ...
(Date:4/5/2020)... ... April 04, 2020 , ... In a time of strife, ... producing non-medical cloth facemasks. , On March 18th when SwaddleDesigns (located in Seattle, ... face masks if no medical-grade facemasks were available, SwaddleDesigns founder& CEO, Lynette Damir ...
Breaking Medicine Technology:
(Date:4/1/2020)... ... ... According to data released by Power to Decide , an estimated 193,110 ... in counties impacted by the implementation of the Title X Family Planning Program “domestic ... Title X resources. , The domestic gag rule requires health providers receiving ...
(Date:4/1/2020)... ... , ... Velocidy Bio ’s Dutch biotech partner, Molecular Biology Systems (MBS), ... testing time for SARS-CoV-2 to eight minutes, compared to current systems that take over ... perform a hundred and eighty (180) amplification runs a day, an almost ten-fold increase ...
(Date:4/1/2020)... ... April 01, 2020 , ... “Medical information is ... law,” says Keller Grover LLP attorney Eric A. Grover. “For that reason, ... the negligent release and disclosure of medical information can, under certain circumstances, give ...
(Date:3/30/2020)... GROVE, Ill. (PRWEB) , ... March 30, 2020 ... ... its name as the coronavirus pandemic sweeps the country. In an effort to ... company’s software solutions are enabling police interaction with community members while minimizing direct ...
(Date:3/28/2020)... (PRWEB) , ... March 27, 2020 , ... ... way of life as COVID-19 cases grow by the day, people of all ... with language disorders—who have difficulties with social interactions in the best of times—the ...
Breaking Medicine News(10 mins):